We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
NVO

Price
50.04
Stock movement down
-1.33 (-2.59%)
Company name
Novo Nordisk A/S
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers - General
Market cap
168.56B
Ent value
388.46B
Price/Sales
0.62
Price/Book
1.40
Div yield
2.34%
Div growth
-0.50%
Growth years
-
FCF payout
-
Trailing P/E
1.78
Forward P/E
1.99
PEG
1.29
EPS growth
18.50%
1 year return
-55.46%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-10-30

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share1.17
Dividend yield2.34%
Payout frequency-
Maximum yield4.84%
Average yield2.21%
Minimum yield0.86%
Discount to avg yield5.25%
Upside potential5.54%
Yield as % of max yield48.25%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield2.34%
Current yield distribution43.61%
Yield at 100% (Min)0.86%
Yield at 90%0.95%
Yield at 80%1.17%
Yield at 50% (Median)2.15%
Yield at 20%3.19%
Yield at 10%3.38%
Yield at 0% (Max)4.84%

Dividend per share

Loading...
Dividend per share data
Years of growth-
CCC status-
Dividend per share1.17
Payout frequency-
Ex-div date18 Sep 2025
EPS (TTM)-
EPS (1y forward)25.18
EPS growth (5y)18.50%
EPS growth (5y forward)1.38%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
NVOS&P500
DGR MR-46.80%-13.74%
DGR TTM16.40%6.60%
DGR 3 years-12.09%5.24%
DGR 5 years-0.50%5.40%
DGR 10 years6.91%7.07%
DGR 15 years13.30%6.12%
Time since last change announced90 days
EPS growth (5y)18.50%
EPS growth (5y forward)1.38%

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E1.78
Price to OCF1.43
Price to FCF2.51
Price to EBITDA1.19
EV to EBITDA2.74

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales0.62
Price to Book1.40
EV to Sales1.44

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Income statement

Loading...
Income statement data
Revenue (TTM)-
Gross profit (TTM)-
Operating income (TTM)-
Net income (TTM)-
EPS (TTM)-
EPS (1y forward)25.18

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash57.02B
Net receivables79.63B
Total current assets195.16B
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets397.44B
Accounts payable24.08B
Short/Current long term debt56.97B
Total current liabilities208.36B
Total liabilities276.92B
Shareholder's equity0.00
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-
Capital expenditures (TTM)-
Free cash flow (TTM)-
Dividends paid (TTM)-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open49.95
Daily high50.54
Daily low49.44
Daily Volume19.9M
All-time high146.91
1y analyst estimate61.57
Beta0.32
EPS (TTM)-
Dividend per share1.17
Ex-div date18 Sep 2025
Next earnings date5 Nov 2025

Downside potential

Loading...
Downside potential data
NVOS&P500
Current price drop from All-time high-65.94%-1.10%
Highest price drop-69.11%-19.00%
Date of highest drop6 Aug 20258 Apr 2025
Avg drop from high-47.88%-2.76%
Avg time to new high-5 days
Max time to new high266 days89 days
COMPANY DETAILS
NVO (Novo Nordisk A/S) company logo
Marketcap
168.56B
Marketcap category
Large-cap
Description
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Employees
78387
Investor relations
SEC filings
CEO
Lars Fruergaard Joergensen
Country
USA
City
Novo Alle
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...